Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australian pharmaceutical company, PharmAust, has acquired a 51% stake in its joint venture (JV) with Curtin University to develop an oral diabetes therapy.
Subscribe to our email newsletter
PharmAust is a unit of Epichem that contributed cash to the university to gain an additional 11% in the JV, proactiveinvestors.com.au reported.
It is believed that the treatment would be used as a front-line therapy to treat type 2 diabetics by delaying the onset of insulin-dependency.
The drug development project is still at the early discovery stage.